Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
Soua A, Gilhodes J, Iat A, Hicheri Y, Saillard C, Rouzaud C, D'Incan E, Rey J, Mohty B, Charbonnier A, Ittel A, Alary AS, Gelsi-Boyer V, Murati A, Lhoumeau AC, Devillier R, Boher JM, Mozziconacci MJ, Vey N, Hospital MA, Garciaz S. Soua A, et al. Among authors: garciaz s. Eur J Haematol. 2024 Dec;113(6):751-757. doi: 10.1111/ejh.14290. Epub 2024 Aug 11. Eur J Haematol. 2024. PMID: 39129130
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: garciaz s. Blood Adv. 2024 Sep 24;8(18):4845-4855. doi: 10.1182/bloodadvances.2024012858. Blood Adv. 2024. PMID: 38941537 Free PMC article.
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Garciaz S, et al. Am J Hematol. 2024 Oct;99(10):1870-1876. doi: 10.1002/ajh.27417. Epub 2024 Jun 20. Am J Hematol. 2024. PMID: 38899566
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: garciaz s. Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15. Am J Hematol. 2024. PMID: 38751104 No abstract available.
[Cancer: The need to believe].
Garciaz S, de Nonneville A, Maraninchi D. Garciaz S, et al. Bull Cancer. 2024 Jun;111(6):550-551. doi: 10.1016/j.bulcan.2024.04.001. Epub 2024 May 6. Bull Cancer. 2024. PMID: 38714464 French. No abstract available.
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
Berton G, Sedaki B, Collomb E, Benachour S, Loschi M, Mohty B, Saillard C, Hicheri Y, Rouzaud C, Maisano V, Villetard F, Corda ED', Charbonnier A, Rey J, Hospital MA, Ittel A, Abbou N, Fanciullino R, Dadone-Montaudié B, Vey N, Venton G, Cluzeau T, Alary AS, Garciaz S. Berton G, et al. Among authors: garciaz s. Leuk Res. 2024 Jun;141:107500. doi: 10.1016/j.leukres.2024.107500. Epub 2024 Apr 15. Leuk Res. 2024. PMID: 38636413 Free article.
Venetoclax Resistance in Acute Myeloid Leukemia.
Garciaz S, Hospital MA, Collette Y, Vey N. Garciaz S, et al. Cancers (Basel). 2024 Mar 8;16(6):1091. doi: 10.3390/cancers16061091. Cancers (Basel). 2024. PMID: 38539426 Free PMC article. Review.
Caspase-2 protects against ferroptotic cell death.
Dawar S, Benitez MC, Lim Y, Dite TA, Yousef JM, Thio N, Garciaz S, Jackson TD, Milne JV, Dagley LF, Phillips WA, Kumar S, Clemons NJ. Dawar S, et al. Among authors: garciaz s. Cell Death Dis. 2024 Mar 1;15(3):182. doi: 10.1038/s41419-024-06560-6. Cell Death Dis. 2024. PMID: 38429264 Free PMC article.
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D'Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Petit C, et al. Among authors: garciaz s. Eur J Haematol. 2024 Apr;112(4):530-537. doi: 10.1111/ejh.14140. Epub 2023 Nov 29. Eur J Haematol. 2024. PMID: 38031389
48 results